SPOTLIGHT: Glumetza approved in Canada


Canada's Biovail and Depomed have received Canadian regulatory approval for Glumetza for Type 2 diabetes. The companies are also expecting a decision from the FDA on Glumetza, which earned an "approvable" letter from the agency. Release

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.